Pear Therapeutics, Inc.

Pear Therapeutics, Inc. went public through its merger with blank-check company Thimble Point Acquisition Corp, ticker THMA, which completed its initial public offering in 2021 targeting the healthcare and life sciences sector. The S-1 registration statement filed on December 23, 2021 formalized Pear Therapeutics' listing on the Nasdaq as a developer of prescription digital therapeutics for substance use disorders and other chronic conditions, representing one of the earlier de-SPAC transactions in the digital health space. The combined company subsequently filed for Chapter 11 bankruptcy protection in January 2023 and ceased operations. Sign up on SpacDesk for full filing histories, sponsor profiles, and deal analytics on THMA and hundreds of other SPAC transactions.